Arbitel AM 5+80 mg Tablet (Amlodipine + Telmisartan 80 mg) – ACI Limited

1. About Arbitel AM 5+80 mg (Amlodipine + Telmisartan 80 mg)

Arbitel AM 5+80 mg is a fixed-dose combination (FDC) of Amlodipine 5 mg and Telmisartan 80 mg, manufactured by ACI Limited, Bangladesh. This formulation contains the maximum telmisartan dose (80 mg) combined with the standard amlodipine 5 mg — providing the strongest RAAS blockade within the Arbitel AM range, with full CCB antihypertensive effect.

Arbitel AM 5+80 mg is the target combination for patients with moderate-to-severe hypertension requiring maximum ARB effect — particularly those with established cardiovascular disease, T2DM with significant proteinuria, or those who need ONTARGET-level telmisartan dosing plus a CCB. It is also the dose used when step-up from Arbitel AM 5+40 mg is required due to inadequate BP control. The combination produces additive antihypertensive action from two complementary mechanisms with a single daily tablet.

2. Mechanism of Action

Telmisartan 80 mg (ARB — maximum dose): Selective AT1 receptor blockade → full suppression of angiotensin II effects → vasodilation, reduced aldosterone, decreased cardiac afterload, renal efferent dilation → blood pressure reduction + renoprotection. PPAR-γ partial agonism at 80 mg dose provides insulin-sensitising and metabolic benefits. t½ 24h — continuous 24-hour RAAS suppression.

Amlodipine 5 mg (Dihydropyridine CCB): L-type calcium channel blockade in vascular smooth muscle → arteriolar vasodilation → reduced peripheral resistance → blood pressure lowering. Vasoselective — minimal cardiac depression at standard doses. Very long t½ (35–50h) → once-daily dosing with smooth BP profile.

Synergy: ARBs counteract the reflex renin activation and sodium retention triggered by CCB-mediated vasodilation — enhancing BP reduction while reducing amlodipine’s ankle oedema side effect. Additive antihypertensive effect equivalent to adding 10–15 mmHg systolic vs either agent alone.

3. Indications

• Moderate-to-severe hypertension requiring maximum ARB + CCB combination
• Cardiovascular risk reduction: Telmisartan 80 mg (ONTARGET dose) + amlodipine for high-risk patients
• T2DM with hypertension and significant nephropathy: Maximum renoprotective ARB dose + CCB
• Step-up from Arbitel AM 5+40 mg when BP target not achieved
• Patients on separate telmisartan 80 mg + amlodipine 5 mg tablets — simplification to single FDC

4. Dosage and Administration

Standard: One tablet once daily. Provides amlodipine 5 mg + telmisartan 80 mg per day.

Initiation: Generally initiated by titration — start on Arbitel 40 mg or Arbitel AM 5+40 mg; step up to 5+80 mg after 4–8 weeks if BP remains above target. In high-CV-risk or severely hypertensive patients, may be initiated directly at 5+80 mg.

Take once daily at consistent time, with or without food.

5. Contraindications

• Hypersensitivity to amlodipine, telmisartan, or dihydropyridines
• Pregnancy (all trimesters — telmisartan teratogenic)
• Severe hepatic impairment
• Cardiogenic shock, unstable angina, significant aortic stenosis
• Aliskiren co-administration in diabetes or eGFR <60 ml/min

6. Warnings and Precautions

Pregnancy: Absolute contraindication. Discontinue immediately on pregnancy confirmation.

Hypotension: At 80 mg telmisartan + 5 mg amlodipine, significant BP reduction expected. Initiate cautiously in volume-depleted or elderly patients; consider starting at lower telmisartan dose. Monitor BP after first dose.

Peripheral oedema: Less common than with amlodipine alone due to ARB effect. Positional oedema (worse evenings) is pharmacological, not heart failure. If troublesome, ensure patient is not also on a calcium channel blocker separately.

Renal/electrolytes: Monitor creatinine and K+ as for telmisartan 80 mg alone. More important at 80 mg dose (more complete RAAS suppression).

Hepatic impairment: Both components have hepatic involvement in elimination. Contraindicated in severe; caution in mild-moderate (max telmisartan 40 mg — use Arbitel AM 5+40 mg instead).

7. Side Effects

Amlodipine: Peripheral oedema (less than monotherapy), headache, flushing, palpitations, dizziness.

Telmisartan 80 mg: Dizziness (increased at higher dose), fatigue, back pain, URTI, diarrhoea, hyperkalaemia.

Combination benefit: Lower ankle oedema vs amlodipine alone. No cough from ARB.

Rare: Gingival hyperplasia (amlodipine), angioedema, hepatic dysfunction.

8. Drug Interactions

• CYP3A4 inhibitors (azole antifungals, macrolides, grapefruit): Increase amlodipine levels — monitor BP
• CYP3A4 inducers (rifampicin): Reduce amlodipine efficacy
• NSAIDs: Reduce telmisartan efficacy; increase renal impairment risk
• Digoxin: Telmisartan raises digoxin Cmax ~50% — monitor levels
• Lithium: Increased lithium toxicity risk
• K+-sparing agents: Additive hyperkalaemia (telmisartan)
• Dual RAAS: Avoid ACE inhibitor or aliskiren combination

9. Clinical Evidence: Telmisartan 80 mg + Amlodipine 5 mg

Multiple RCTs confirm that ARB + CCB combinations provide greater BP reduction (additional 8–12 mmHg systolic) than either agent alone. Specific to telmisartan + amlodipine, the TEAMSTA trials demonstrated: superior 24-hour ambulatory BP control vs amlodipine alone, less ankle oedema (22% vs 44% with amlodipine monotherapy), and no metabolic deterioration. In diabetic hypertensive patients, ARB + CCB combinations demonstrate greater proteinuria reduction and renal event risk reduction than ARB + thiazide, supporting Arbitel AM 5+80 mg as a preferred combination for T2DM nephropathy with uncontrolled hypertension.

10. Why Arbitel AM 5+80 mg for Maximum Effect?

Arbitel AM 5+80 mg delivers: (1) Maximum telmisartan RAAS blockade (80 mg — ONTARGET evidence dose); (2) CCB vasodilation (amlodipine 5 mg — standard effective dose); (3) 24-hour coverage from both components; (4) Reduced pill burden — one tablet vs two; (5) Reduced amlodipine oedema vs amlodipine alone; (6) No cough. This makes it ideal for Bangladesh’s high-burden hypertensive-diabetic patient population where adherence, tolerability, and comprehensive cardiovascular protection are all essential.

11. Hypertension Management in Bangladesh

Hypertension affects approximately 21–27% of Bangladeshi adults, with rates exceeding 50% in diabetic patients. Multiple drug therapy is required in >70% of cases to achieve guideline-recommended targets. The ARB + CCB combination (Arbitel AM) is recommended as a preferred combination by international guidelines (ESH, JNC, WHO/ISH) and is particularly suitable in the Bangladeshi population due to high ACE-inhibitor cough rates (where ARBs replace ACEi), high diabetes co-morbidity (ARB renoprotection), and hot climate conditions (amlodipine well-tolerated in tropical settings vs beta-blockers which can cause fatigue).

12. ACI Limited Arbitel AM Range

Arbitel AM 5+40 mg and Arbitel AM 5+80 mg provide two combination strengths for flexible hypertension management. Both in a single once-daily film-coated tablet from ACI Limited, Bangladesh’s trusted pharmaceutical manufacturer. Complete antihypertensive coverage alongside the Arbitel Plus range (+ HCT diuretic) for triple-class combination therapy when required.

13. Storage

• Below 30°C, cool, dry, away from moisture and light
• Original blister. Keep out of children’s reach.
• Do not use after expiry date.

Frequently Asked Questions (FAQ)

Q1: What is Arbitel AM 5+80 mg used for?

Arbitel AM 5+80 mg is a maximum-strength ARB + CCB combination for moderate-to-severe hypertension. It contains telmisartan 80 mg (maximum ARB dose, ONTARGET evidence for cardiovascular protection) + amlodipine 5 mg (calcium channel blocker). Used when Arbitel AM 5+40 mg is insufficient for BP control, or when maximum renoprotection is needed in T2DM nephropathy, or when establishing cardiovascular risk reduction therapy for high-risk patients. Produces additive BP reduction with two complementary mechanisms in one daily tablet.

Q2: How does Arbitel AM 5+80 mg differ from Arbitel AM 5+40 mg?

The amlodipine dose is identical (5 mg) in both — the difference is telmisartan: 40 mg vs 80 mg. Arbitel AM 5+80 mg provides maximum RAAS blockade: stronger BP reduction (approximately 3–5 mmHg additional systolic vs 40 mg), full cardiovascular risk reduction (ONTARGET 80 mg evidence), and maximum renoprotection in diabetic nephropathy with significant proteinuria. The 5+40 mg formulation is the starting combination; 5+80 mg is the step-up target dose. Both are once-daily, with identical tolerability profiles except for slightly higher dizziness rates at the 80 mg dose.

Q3: Can Arbitel AM 5+80 mg be used in patients with both hypertension and heart disease?

Yes, with considerations. Amlodipine is beneficial in stable angina — it reduces myocardial oxygen demand through vasodilation. Telmisartan provides cardiovascular risk reduction (ONTARGET trial) and is safe in established CAD, peripheral arterial disease, and post-stroke patients. However, in patients with heart failure with reduced ejection fraction (HFrEF), amlodipine is not recommended (does not improve outcomes and may worsen congestion). ARBs such as telmisartan are used in HF when ACE inhibitors are not tolerated. Your cardiologist will determine the appropriate combination based on your specific cardiac condition.

Q4: What monitoring is required while taking Arbitel AM 5+80 mg?

Regular monitoring includes: Blood pressure — home monitoring recommended to assess daily control; target <130/80 for T2DM patients, <140/90 for general hypertension. Renal function (creatinine/eGFR) and serum potassium — at baseline, 4–6 weeks after initiation, then annually (or more frequently in CKD). Urine albumin:creatinine ratio (ACR) — annually in diabetic patients to assess renoprotective response. Liver function — baseline in patients with liver disease. Report any significant ankle swelling, symptoms of hypotension (dizziness on standing), or muscle cramps to your physician.